Cargando…
Coordination of stress signals by the lysine methyltransferase SMYD2 promotes pancreatic cancer
Pancreatic ductal adenocarcinoma (PDAC) is a lethal form of cancer with few therapeutic options. We found that levels of the lysine methyltransferase SMYD2 (SET and MYND domain 2) are elevated in PDAC and that genetic and pharmacological inhibition of SMYD2 restricts PDAC growth. We further identifi...
Autores principales: | Reynoird, Nicolas, Mazur, Pawel K., Stellfeld, Timo, Flores, Natasha M., Lofgren, Shane M., Carlson, Scott M., Brambilla, Elisabeth, Hainaut, Pierre, Kaznowska, Ewa B., Arrowsmith, Cheryl H., Khatri, Purvesh, Stresemann, Carlo, Gozani, Or, Sage, Julien |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cold Spring Harbor Laboratory Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4826394/ https://www.ncbi.nlm.nih.gov/pubmed/26988419 http://dx.doi.org/10.1101/gad.275529.115 |
Ejemplares similares
-
SMYD3 links lysine methylation of MAP3K2 to Ras-driven cancer
por: Mazur, Pawel K., et al.
Publicado: (2014) -
Discovery and Characterization
of a Highly Potent and Selective Aminopyrazoline-Based in Vivo Probe
(BAY-598) for the Protein Lysine Methyltransferase SMYD2
por: Eggert, Erik, et al.
Publicado: (2016) -
Smyd3 regulates cancer cell phenotypes and catalyzes histone H4 lysine 5 methylation
por: Van Aller, Glenn S., et al.
Publicado: (2012) -
Discovery of an Allosteric Ligand Binding Site in SMYD3 Lysine Methyltransferase
por: Talibov, Vladimir O., et al.
Publicado: (2021) -
LLY-507, a Cell-active, Potent, and Selective Inhibitor of Protein-lysine Methyltransferase SMYD2
por: Nguyen, Hannah, et al.
Publicado: (2015)